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1. Introduction 
Giant cell arteritis (GCA) is a primitive systemic vasculitis related to a sub-acute 
inflammatory panarteritis, histologically characterized by segmentary and plurifocal 
damage, with giant cells and destruction of the internal elastic lamina. GCA involves large 
and medium sized vessels in subjects over 50, particularly between 75 and 85, and is more 
common in women (7:3sex-ratio). This arteritis preferentially affects the external carotid and 
its branches, and more specifically the superficial temporal artery, which explains the usual 
clinical signs of the disease which are headaches, tenderness and sensitivity of the scalp, 
painful thickening of the temporal arteries associated with absence of pulsation, and jaw 
claudication. However, this description of GCA was enriched in 1938 by the first 
observations of « extra-cranial » manifestations. 
A diagnosis of GCA is usually suspected in the elderly subject on the association of focal 
signs of arteritis prevailing in the head, with a more or less febrile alteration of the general 
health condition and an inflammatory syndrome. The classification criteria of GCA most 
used are those of the American College of Rheumatology and which date back to 1990. 
Nevertheless, GCA, because of the potential ubiquity of the pathological process, can occur 
in atypical forms, which renders the etiological approach more complex. The risk is 
therefore a delay in diagnosis which can jeopardize the prognosis of this disease. 
In this chapter, we will approach different atypical aspects of GCA, which can all be 
inaugural of the disease, whose prognosis will depend on their early recognition. They 
include aorta and its main branches involvement except arteritis of the branches of the 
external carotid artery, heart, lung, neurologic, genital and musculoskeletal manifestations. 
2. Aortitis and limb arteritis in giant cell arteritis 
The diagnosis of GCA is based on clinical, biological and histological elements described in 
the classification criteria defined by ACR in 1990. The diagnosis is evident in the case of 
clinical manifestations relative to the involvement of the external carotid branches.  
However, temporal arteritis is not systematic, and involvement of the aorta and its main 
branches may be isolated. In this case, diagnosis is complicated by a clinical presentation 
which is often poor and non-specific, and by the difficulty of obtaining histological proof; 
the new methods of imagery that we are going to describe can then be useful in diagnostic. 
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GCA is one of the three main causes of inflammatory aortitis, besides Takayasu's arteritis 
and Behçet’s disease (Launay & Hachulla, 2003). However, involvement of the large vessels, 
and specifically the aorta, is often little known.  Data from series of autopsies evaluate the 
frequency of aortic involvement up to 70 % during GCA. In the series of Hervé et al. (2006), 
the frequency of thoracic and abdominal involvement diagnosed by Computer Tomography 
(CT) scan were close (73 and 82 % respectively); moreover, concomitant thoracic and 
abdominal involvement was frequent, since it concerned 55 % of the patients. In the study of 
Agard et al. (2009), 22 patients and 22 controls were screened by CT scan for aortic 
involvement. Thickening of the aortic wall was more frequent among patients than controls 
(45.4% versus 13.6%; P 0.02). Aortic thickening was located on the ascending part of the 
thoracic aorta in 22.7% of the patients, with no evidence of thickening in the controls (P 
0.05). Thickening of the abdominal aortic wall was noted in 27.3% of the patients and none 
of the controls (P  0.02). 
Aortic involvement may be the mode of revelation of the disease. It can also occur during 
corticosteroid decrease or withdrawal in patients carrying a known GCA. The clinical 
presentation can be limited to a febrile syndrome, an alteration of the general state of health 
and an inflammatory syndrome. The existence of inflammatory back pains is not systematic. 
The clinical diagnosis of aortic lesion is often difficult and late in GCA, due to the long latency 
of this involvement and the absence of clinical presentation (Bossert, 2010). Aortic lesions 
represent yet another major cause of morbidity and mortality during GCA. They can actually 
be complicated by aneurisms, aortic dissections and less frequently stenosis. Increased 
frequency of aortic aneurisms during GCA is established and they expose the patient to the 
risk of potentially fatal accidents (embol, dissection). In 1995, Evans et al. showed on a 
retrospective series of 96 patients suffering from GCA a risk 17.3 times higher of developing a 
thoracic aneurism and 2.4 times higher of developing an isolated abdominal aneurism, in 
comparison with the population of the same age and sex. In 2003, out of a cohort of 168 
patients with GCA, Nuenninghoff et al. (2003) found 30 cases (18 %) of aortic aneurisms, 18 of 
them in the chest; nine were complicated by aortic dissection, with seven deaths. 
Arterial involvement in GCA is not limited only to the thoracic or abdominal aorta. The 
GCA may be revealed by a lesion in the upper or lower limbs. 
Upper and/or lower limb inflammatory arteritis during GCA is not exceptional occurring in 
3 to 16% of patients. It is rarely reported in the literature but is probably under-estimated as 
it is often low symptomatic (Assie & Marie, 2011). 
Hamrin et al. were among the first authors as early as 1965 to draw attention to the 
possibility of “extra-cranial” arterial involvement through the existence of arterial murmurs 
on the trajectories of the limb arteries. It must not be neglected by the clinicians managing 
these patients due to the severe ischemic complications that it can trigger, amputation being 
necessary in 5.6 to 15.8 % of cases (Assie & Marie, 2011). 
In the review of 318 cases published by Assie and Marie (2011), it can be noted that the 
patients present more often a lesion in the upper (63.1 %) than in the lower limbs (32.2 %); 
with concomitant involvement of both the upper and lower limbs arteries in 4.7 %. It was 
also observed that the arterial sites involved are in order of frequency:  
 subclavian arteries (53.2 %), axillary arteries (37.3 %), brachial arteries (24 %) ;   
 iliac arteries (0.43 %), common femoral arteries (2.6 %), superficial femoral arteries  
(24.9 %), deep femoral arteries (10.3 %), popliteal arteries (16.3 %), tibio-peroneal trunk  
(1.3 %), and tibial arteries.  
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If the upper and/or lower limb arterial involvement can be the mode of revelation of GCA, 
it can also occur during corticosteroid decrease or withdrawal in patients with a known 
GCA. In the observation by Skopinski et al. (1997), for four women and one man, aged from 
67 to 77, the mode of revelation was intermittent claudication of an upper limb in three cases 
and bilateral Raynaud’s syndrome in one case. The discovery was accidental in one case (the 
general practitioner was anable to measure blood pressure). In all cases there was an 
absence of peripheral pulse, and it was impossible to measure blood pressure on the side 
involved. All the patients had a biological inflammatory syndrome. Arteriography showed 
that all the patients had long and tight stenosis on the subclavian, axillary and humeral 
arteries. The biopsy of the temporal artery, carried out in all five cases, was positive in three.  
A surgical act of revascularisation was only necessary once. Evolution of the clinical 
symptomatology and the inflammatory syndrome was constantly favourable under 
prednisone. Furthermore Tazi et al.(1997) reported the case of a woman of 67 with no risk 
factors for atheroma, hospitalised for lower limbs  ischemia relative to bilateral occlusion of 
the superficial femoral arteries. The femoral artery biopsy did not reveal any thrombosis but 
showed the inflammatory nature of the lesion confirming the diagnosis of GCA. Upper 
and/or lower limb arterial involvement occurs more frequently in women; in the literature 
(Assie & Marie, 2011), 58.8 % of the patients were women with a median age of 67. The 
clinical manifestations included intermittent claudication of a limb (68.6 %), decrease in 
pulse or absence of a peripheral, limb ischemia (17.9 %), even gangrene of a limb/toe/finger 
(6.4 %). However limb arterial involvement does not always have a clinical expression in the 
early stages. Thus involvement must not be neglected by physicians managing these 
patients due to the severe ischemic complications it can trigger.  
In this context, aortitis appears frequent in patients with an upper and/or lower limb 
arterial involvement complicating a GCA. Weyand and Goronzy (1999) noted an aortitis in 
10 to 15 % of these patients. Likewise, in a recent series, an aortic localization was associated 
with a limb arterial involvement in up to 68.9 % of the cases (Assie et al.2011). In view of the 
potential gravity of aortic lesions, it would appear justified to carry out a systematic 
exploration of the aorta and its branches to look for an aortitis in patients presenting a GCA. 
Interestingly, in the work of Assie et al.(2011), headaches (25 % vs. 77 %), jaw claudication 
(11 % vs. 35 %), tenderness and sensitivity of the scalp (8 % vs. 67 %) and a positive 
temporal artery biopsy (69 % vs. 95 %) were all less frequent in the group carrying an upper 
and/or lower limb arterial involvement than in that who had none. Likewise, Hervé et 
al.(2006) found less frequent usual inaugural signs of GCA in cases of aortitis. Brack et al. 
(1999) mentioned that the group of patients carrying a large vessel involvement, compared 
with those with a predominant cephalic involvement, were younger (66 vs 72) and had less 
often the classical signs of GCA (headaches, jaw claudication, visual disorders). 
Different complementary non-invasive vascular examinations can be carried out to search 
for a limb or aortic arterial involvement. Arterial Doppler ultrasound is a simple non-
invasive examination for studying large arteries in patients. In GCA, arterial inflammation is 
determined by a circular thickening of decreased echogenicity of the vascular wall around 
the arterial light (halo of decreased echogenicity). Moreover, studies have found a 
correlation between the type and the seat of the arterial lesions revealed by arterial Doppler 
ultrasound and angiography, which confirm the high sensitivity of this examination in 
detecting upper and/or lower limb arterial involvement in GCA (Schmidt et al. 2005; Agard 
et al.2009). 
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On the other hand, arterial Doppler ultrasound presents a limited interest for following  
up arterial involvement in the patients treated; the thickening of the vascular wall would 
appear to persist under corticosteroids, which complicates the correlation between  
the ultrasound data and GCA activity. Angioscan is useful as an examination to detect aortic 
involvement and limb arterial involvement, and it has the added advantage of being  
more available and shorter than the MRI angiography. Therefore, Agard et al.(2009)  
and Hervé et al. (2006) highlighted the diagnostic interest of the angioscan for the diagnosis 
of inflammatory aortitis in patients suffering from a GCA, as this examination makes  
it possible to visualize directly the suggestive anomalies of the aortic wall (circumferential 
parietal thickening, regular and homogeneous, more than 3 mm thick). In addition to  
this, we can note the interest of the angioscan for the follow-up of GCA aortitis (Hervé  
et al. 2006).  
Lastly positron emission tomography (PET) with 18 FDG, a noninvasive metabolic imaging 
modality that is well-suited to the assessment of activity and extent of large vessel vasculitis, 
also appears to be a promising technique. Contrary to the previous radiological 
examinations, it can detect vasculitis lesions all over the body and it is more sensitive to 
show inflammatory vascular wall process (Belhocine et al 2002 ;Liozon et al.2010 ) (figures 1-
3); these data suggest the potential clinical interest of the PET in the vascular disease 
activity, extension and follow-up of patients with GCA (figure 4).  
 
 
 
A: PET image. 
B: CT-scan image. 
C: images fused PET and CT-scan. 
Fig. 1. Coronal view of Positron Emission Tomography (PET) showing hyper metabolism of 
the thoracic and abdominal aorta walls extending to the subclavian arteries indicating 
aortitis. 
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                   A                                               B                                              C 
Fig. 2. Sagittal view of inflammation of the descending thoracic aorta (A : PET, B: CT-scan, 
C: fusion of the PET and CT-scan images). 
 
 
          A                                                  B                                                  C 
Fig. 3. Axial view showing hyper metabolism of the ascending and descending wall of 
thoracic aorta, indicating aortitis (A: PET, B: CT scan, C: images fused PET-CT). 
One of the limits of PET is its availability and its spatial resolution which does not make  
it possible to highlight the involvement of arteries with a size of less than 4mm (Loizon  
et al. 2010).  
The treatment of vascular lesions is the same than classical form of GCA relying on 
corticosteroids. The hypothesis of administration of a higher or longer dose of 
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corticosteroids in the case of aortic and large artery involvement does not reside on any 
element of proof. The occurrence of thrombotic complications during GCA also leads to 
discussion on the interest of a treatment by antiplatelet drug or anticoagulants, whose use is 
not codified. Nesher et al.(2004), in a non-randomized study of 175 GCA patients, reported a 
reduction of the incidence of neurological ischemic complications in the group of patients 
treated with aspirin compared with the group which did not receive any (4 % vs. 29 %). In 
another series, Lee et al. (2006) also mentioned that the risk of occurrence of ischemic 
complications was three times higher in the group of patients who did not receive an aspirin 
treatment against the treated group. A few caveats, however, are necessary before one 
recommends that low-dose aspirin should be added as standard of care in GCA.  
 
 
A               B 
Fig. 4. Maximal Intensity Projection (MIP) of PET showing hyper metabolism of the thoracic 
and abdominal aorta extending to the subclavian arteries, before (A) and after three months 
of steroids (B), pointing out the decrease of the inflammation of the arterial walls. 
There are very few data, in the form of isolated observations only, relative to the usefulness 
of anticoagulants in the initial stage of GCA. For some authors, the use of anticoagulants in 
this indication resides on the following elements: (1) Giant cell arteritis is a granulomatous 
arterial disease causing sometimes very tight arterial stenosis which can be the seat of an 
intraluminal thrombosis; (2) the blood rates of the von Willebrand procoagulating factor are 
increased during GCA. At present, due to the lack of open or randomized studies having 
analysed the interest of anticoagulants in this context, anticoagulation cannot be 
recommended systematically for these patients. In practice, in the case of a severe acute 
ischemic limb involvement, an anticoagulant treatment is usually prescribed. 
Immunosuppressive treatments have not been evaluated in these forms. The role of 
vasodilators remains to be determined. In the series of Benjilali et al. (2009), intravenous 
prostaglandins had given a good result in a patient with threatening ischemic lesions, in 
association with corticosteroids and anticoagulants. 
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To date there is no consensus for the choice of imagery and the rhythm of supervision of 
aortitis. The follow-up must be regular and on long-term, even after the withdrawal of 
corticosteroids. As certain authors suggest (Garcia et al.2008), supervision once a year by 
lung X-ray, transthoracic echocardiography and Doppler ultrasound of the abdominal aorta 
would seem to be appropriate. Thoracic-abdominal scan with injection and 3D 
reconstruction is also efficient in this indication (Hervé et al.2006). Lastly, PET would appear 
to be more interesting than CT scan to evaluate the response of the aortitis to corticosteroids; 
The vascular metabolic signal disappears, despite the persistence of a perivascular cuff in 
CT scan (Liozon et al.2010). 
3. Mesenteric artery involvement 
Described for the first time by Hamrin et al. in 1965, mesenteric inflammatory arteritis is rare 
in the course of GCA. The majority of articles do not mention GCA among the causes of 
mesenteric ischemia. From this point of view, analysis of the literature has enabled us to list 
33 cases of mesenteric inflammatory arteritis in patients carrying GCA. In the review of the 
literature (Lorthior et al.2008), diagnosis of mesenteric inflammatory arteritis and GCA was 
concomitant in 57.6 % of the cases; in the other patients, mesenteric inflammatory arteritis 
appeared in the development of GCA, usually in the first three months following its 
diagnosis. The diagnosis of GCA mesenteric arterial lesions is often difficult due to the 
absence of specific clinical presentation. In all 33 cases, the patients presented: abdominal 
pains (97%) which were rarely characteristic of mesenteric angina (15.2 %); an occlusive 
syndrome (42.4 %) or a digestive haemorrhage (6.1 %), and the last patient was 
asymptomatic from the digestive point of view. These elements suggest that the prevalence 
of the mesenteric inflammatory arteritis is probably under-estimated during GCA; 
systematic prospective, vascular imaging studies could make it possible to determine its 
prevalence along with the incidence in these patients. If the final diagnosis of mesenteric 
inflammatory arteritis resides, in theory, on the histological examination, arterial biopsies of 
this kind are an invasive examination, and are not carried out in practice. Colour Doppler 
ultrasound is an inexpensive and easily available examination, and frequently used at the 
beginning. At present, the angioscan would appear to be a useful examination to objectivise 
mesenteric arterial involvement; this examination makes it possible to highlight directly the 
suggestive anomalies of the mesenteric artery wall: a regular and homogeneous  
(> 3 mm) thickening, a luminal stenosis and also a periarterial halo and the absence of 
calcification (Lorthioir et al. 2008). MRI angiography could also be useful for the diagnosis of 
mesenteric arterial lesion but complementary studies to assess its relevance are necessary. 
Lastly, PET could also be a useful diagnostic technique in this indication; however, today, it 
is not possible to analyse small vessels (diameter under 4 mm) with the PET (Liozon et al. 
2010). At present, mesenteric arterial lesions are a major cause of morbidity and mortality in 
GCA.  They can be complicated by chronic mesenteric ischemia, mesenteric infarcts, 
ischemia-related intestinal pseudotumors, or digestive perforations. Some authors (Scola et 
al. 2008; Sujobert et al. 2008) suggest that the prognosis of patients with only prednisone was 
better than that of patients who received a medico(prednisone)- surgical treatment; these 
data seem, partly, to be explained by the fact that the patients treated surgically presented 
more severe mesenteric arterial complications. 
Some patients received, in association with steroids, a complementary treatment with 
antiplatelet drug. However, the efficiency of these treatments in the reduction of the risk of 
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thrombosis, in patients suffering from a mesenteric giant cell arteritis, remains to be 
determined. 
4. Pericarditis an unusual manifestation 
Pericarditis during GCA is rarely reported. In the literature, we were only able to find 
twelve observations in 20 years (Bablekos et al. 2006; Dupond et al. 1982; Clementz et al. 
1989; Garewal et al. 1981; Guillaume et al. 1991; B; Guindon et al. 2007; Preston et al. 1991; 
Pedro-Botet et al. 1996; Matsue et al. 2011; Moulis et al. 2010; Stanley et al. 1989 & Valstar et 
al. 2003). In nine of these cases, cardiac symptoms including chest pain, exertional dyspnea 
or pericardial fremitus were present, but in three of the cases, the pericarditis was silent and 
was discovered on chest X-ray anomaly (Guindon et al. 2007; Miller 1996; Pedro et al. 1996). 
In this observations, the classical electrocardiographic anomalies of pericarditis (PR segment 
depression, repolarization anomalies) are not constant and one case only has been described 
with signs of ultrasound tamponade which did not however necessitated drainage, the 
hemodynamics being stable and progression satisfactory with corticosteroids (Valstar et al. 
2003).The pericarditis was inaugural of GCA in all the cases, except one incidence of a 
relapse after one year, following the sudden interruption of the corticosteroids (Valstar et al. 
2003). In all the reported cases, the pericarditis was always regressive under corticosteroids. 
In the review of several cases of pericarditis during GCA carried out by Bablekos et al. 
(2006), the authors point out that the classical signs of the disease are only present in 2/3 of 
the cases and highlight the interest of looking for GCA in inflammatory « idiopathic » 
pericarditis in subjects over 50 (Granel et al. 2001).  
The pathogenesis is not known but several hypotheses can be advanced: inflammatory 
cytokine storm, deposit of complex immunes, and vasculitis of the pericardial arteries or 
interstitial inflammatory lesion of the pericardium with or without granulomas. It is at 
present impossible to know its prevalence, especially as pericarditis is not symptomatic in 
all cases and not searched for by systematic echocardiography. Only a study to evaluate 
systematic echocardiography during GCA (on diagnosis or in the case of recurrence) could 
allow us to appreciate its real prevalence and evaluate prospectively its prognostic value. 
The treatment and the progression of pericarditis do not seem to differ from those of GCA: 
corticosensitivity to usual doses is excellent. Even though the risk of chronicity is difficult to 
appreciate (monitoring in nearly all the observations published does not exceed six months), 
no case of progression towards constriction have been reported. 
In conclusion, we wish to emphasize that pericarditis needs to be added to the list of the 
numerous unusual presentations of GCA. We suggest relevance of a temporal artery biopsy 
in elderly patients with general symptoms associated with so-called “idiopathic 
pericarditis” even in the absence of typical manifestations of temporal arteritis. 
5. Giant cell arteritis and myocarditis 
Myocarditis belongs among the other cardiac manifestations described during GCA. 
Classical clinical presentation of GCA is rarely associated. Temporal artery biopsy is 
essential in confirming the diagnosis of GCA and proposing a specific therapy, in order to 
prevent cardiovascular ischemic complications. Etiological research of myocarditis must 
lead to discuss viral or bacterial diseases in the first instance. Certain auto-immune diseases 
must also be suspected. GCA myocarditis physiopathology is not known and only 3 cases 
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are reported in the literature: two cases of myopericarditis (with alteration of the left 
ventricular systolic ejection fraction) were described by Teixera et al. (2003)] in two female 
patients, respectively aged 78 and 65. It must be noted that in these two observations, at no 
time were any clinical signs suggestive of GCA found; biopsy of the temporal artery was 
motivated only by the importance of the alteration of the general health condition in an 
unexplained inflammatory context. A case was described in a woman of 82 hospitalised for 
chest pain which had for 3 months an alteration of the general health condition with a 
weight loss of 4 kg, bitemporal headaches and jaw claudication. Transthoracic 
echocardiography showed a minimal lamina of pericardial effusion, retained left ventricular 
systolic ejection fraction with normal coronography (Pugnet et al. 2009). Although rare and 
certainly under-estimated, myocarditis must be known as an expression of GCA with rapid 
favourable progression under treatment. The diagnosis of GCA must remain in mind faced 
to myocarditis of the elderly patients with healthy coronaries. 
6. Coronary arteritis and giant cell arteritis 
Cases of giant cell arteritis in isolated coronary arteries, resulting in myocardial infarction, 
are unusual and have been infrequently reported in the literature (Cohle et al 1982; Kumar 
et al.2002; Long-Wei et al 2007 & Saito et al 1994). It is difficult to formally relate signs of 
coronary heart disease to GCA. However, histologically documented observations describe 
a thrombosis which develops as a consequence of the coronaritis with giant cells. In most of 
these reports, the definite diagnosis was based on postmortem examination or on 
atherectomy specimen evaluation (Saito et al 1994). In the case of Long-Wei and al. (2007), 
the histopathological diagnosis was based on evaluation of the native heart after heart 
transplantation. This is the first such case mentioned in the heart transplant literature in 
which native heart evaluation was used to confirm this diagnosis.The involvement of the 
coronary arteries is associated with a very severe prognosis. These cases suggest that 
coronary artery giant cell arteritis should be added to the list of differential diagnoses for 
patients suspected of myocardial infarction due to coronary artery disease or dilated 
cardiomyopathy. Treatment of GCA coronaritis is not codified. 
7. Respiratory manifestations 
The respiratory manifestations of GCA are rare and little known. They can be associated 
with more typical signs of the disease, but they can also be inaugural and the cause of a 
delay in care. Cassarou et al. (2010) reported eight observations in 2010 which illustrate the 
respiratory involvement of the disease. In two observations, the pleuropulmonary 
manifestations were concomitant with the clinical signs of GCA. In 5 observations out of 8, 
the pulmonary signs were inaugural with a time lapse of 10 to 21 days before the 
appearance of the clinical signs suggesting GCA whereas in one observation, these last were 
never observed. 
Cough is the most frequent respiratory manifestation of GCA; pleural effusions and 
alveolar-interstitial involvement were rarer. The first form of GCA presenting as a chronic 
cough was described in 1956 by Valleteau de Mouillac. Cough, whether accompanied by a 
fever or an inflammatory syndrome, can be the first sign of the disease and precede the 
other signs by several months. In the study by Becourt-Verlomme et al. (2001) which dealt 
with the inaugural signs of the disease, out of 260 patients with GCA, cough was present in 
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8 % of the patients. In the study by Letellier et al. (2003) which analyzed 285 patients with 
GCA, 57 patients (20 %) presented a dry cough with a prolonged fever and this symptom 
was inaugural in 22 of them (8 %).The cough is irritative, sleep-depriving, and resists 
symptomatic treatment. After having eliminated the most frequent causes of chronic cough, 
the age and the importance of the inflammatory syndrome should suggest GCA among the 
diagnosis hypotheses. To illustrate this involvement, Kassem et al (2010) report the 
observation of a woman of 70 hospitalized for a dry cough developing over three months, 
associated secondarily with fever and loss of weight. She had no other functional signs, the 
clinical examination showed no particularities and it had been identified as a biological 
inflammatory syndrome. A lung, sinus or digestive pathology was looked for but the chest 
abdomen pelvis scan was considered as normal. Bronchial fibroscopy found a congestive 
bronchial mucous with no endoluminal lesions. Taking age into consideration, the alteration 
of the general state of health and unexplained inflammatory syndrome, a biopsy of the 
temporal artery was carried out whose histological analysis was characteristic of GCA. The 
cause of cough in GCA has not been formally identified: it could be related to a pharyngeal 
involvement whose vascularisation depends on the internal maxillary artery, it could be 
secondary to an irritation of the cough-exciting centers located in the airways, the 
diaphragm or the esophagus from the arterial inflammation and finally cough may also be a 
sign of inflammatory lung involvement which may affect the pulmonary arteries, lung 
parenchyma and pleura. The evolution of the cough is parallel to that of the disease, and 
regresses rapidly under steroids with possibility of relapse during decrease or withdrawal 
of the treatment.  
Cases of pulmonary embolism related to GCA are exceptional in the literature (Andrès et al. 
2003; Chassagne et al. 1995; Landrin et al. 1997 & Radhamanohar et al. 1991). Chassagne et al 
(1995) report the case of a woman of 86 with a biopsy proven GCA with a clinical and 
biological rapid favorable outcome under steroids. She was later hospitalized for febrile 
dyspnea with cough which revealed pulmonary lesions resulting in a lung infarction with 
excavation with partial thrombosis of the left pulmonary artery. The favorable development 
of the symptoms was rapid and durable with an increase in the dosage of steroids (with no 
associated anticoagulant treatment) which strengthened the hypothesis of an inflammatory 
thrombosis of the pulmonary artery. In the case reported by Andrès et al. (2003), 
thrombophilia tests (antithrombin, proteins C and S, factor V Leiden, antiphospholipids and 
circulating anticoagulant) were negative as was the search for deep vein thrombosis. The 
post-mortem histological examination revealed a giant cell arteritis infiltrating the three wall 
linings of the artery with regards to the thrombus. 
In the literature, pleural effusion may be unilateral or bilateral, of mild to moderate 
abundance, generally well-tolerated and not very symptomatic. It may be isolated or 
associated with a pericardial effusion and sometimes be inaugural of the disease, and render 
diagnosis difficult (Valstar et al. 2003). The analysis of the liquid is reported around ten 
times in the literature; exsudative, sterile and with a cellularity of 600 to 3200 elements/mm3 
with a predominance of either neutrophils or lymphocytes (Colnot 1996.; Deraedt et al. 1994 
& Marie et al. 2004). The physiopathology of the pleural involvement is not known. Blind 
pleural biopsies report a non-specific inflammatory reaction or a hyperplasia of mesothelial 
cells in inflammatory nodules (Colnot 1996). Examination of the pleura is, particularly in 
histology, more profitable for eliminating differential infectious and neoplastic diagnosis 
than for confirming GCA. The corticosensitivity of the pleural involvement is specific to the 
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disease with rapid regression of the effusions, and sometimes total regression in a few days 
(Colnot 1996.; Deraedt et al. 1994 & Marie et al. 2004).  
Parenchymal pulmonary involvement is rare and described inaugurally for a relapse of the 
disease after reduction or withdrawal of corticosteroids. It is often accompanied by cough 
but may also be discovered fortuitously in imagery. In practice, the lesions are probably 
under-diagnosed and under-reported, the cases described in the literature being old ones. 
The interstitial involvement is predominant of reticulated or reticulo-micronodular type 
with predominance of the basal type (Karam & Fulmer 1982). Macronodular involvement 
(Bradley et al. 1984) can take a single or multiple pseudotumoral aspect, sometimes 
excavated, and leads to discussion on neoplastic aetiology, rheumatoid nodules, infectious 
(tuberculosis, nocardiosis) or inflammatory (Wegener) granulomatosis. Bronchial fibroscopy 
and bronchoalveolar lavage play a major role in the bacteriological investigation and the 
search for a bronchial neoplasia when there are radiological anomalies. On the other hand, 
they do not supply any diagnostic specificity: the macroscopic aspect shows an 
inflammatory bronchitis, the cytology of the bronchoalveolar lavage is polymorphic with 
macrophage predominance in some observations or a lymphocytic alveolitis. Diagnostic 
procedure of the biopsies carried out during the bronchial fibroscopy is limited. In the 
observations of Cassarou et al. (2010), the biopsies revealed a non-specific inflammation. The 
observations of Cassarou et al. (2010) also illustrate well certain problems in diagnosing the 
respiratory forms of GCA: when lung involvement precedes, sometimes by a few weeks, the 
clinical signs of GCA and when the histology of the temporal artery is not typical or when it 
is negative. The differential diagnosis may be difficult with other small and medium sized 
vessel vasculitis with a much more frequent pulmonary involvement, especially as overlaps 
were reported between GCA and Churg-Strauss syndrome (Vidal et al. 1992), microscopic 
polyangitis, periarteritis nodosa (Godeau et al. 1984) or Wegener’s disease (Astudillo et al. 
2008). A GCA preceding a Wegener’s disease by a few years has also been reported 
(Garrouste et al. 2008). In the eight observations reported by Cassarou et al. (2010), the 
clinical and radiological lung involvement is sensitive to corticosteroids with no relapse 
observed. In the same way, Carli et al. (2001) report 2 cases of scattered multiple pulmonary 
nodules in a context which was suggestive of GCA and totally reversible under 
corticosteroids after searches for neoplasia have given a negative result.    
The knowledge of these different respiratory manifestations during GCA (persistent  
cough, nodules, pleural effusion) is useful for the clinician. It helps him in prescribing non 
invasive investigations or even a presumptive steroids therapy, in an often old and 
weakened patient. 
8. Neurologic manifestations 
Cerebral vascular accidents (CVA) were reported in 3 to 6 % of cases (Nesher et al. 2000) but 
have never revealed GCA. Central nervous system findings in GCA are the result of 
thrombosis of the carotid or vertebral arteries, rather than of a primary neurogenic process 
or intracranial arteritis. GCA affects vessels that contain, internal elastic lamina. As 
intracranial vessels lose their internal elastic lamina 5 mm beyond the point of dural 
perforation, more distal intracranial arteritis is rare. In fact, clinical and pathologic findings 
suggest that these ischemic events are due to involvement of extradural vertebral and 
carotid arteries with high-grade stenosis or occlusion rather than intracranial vasculitis. 
Salvarani et al. (2006) confirm that obstruction and occlusion of internal carotid and/or 
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vertebral arteries are the most frequent causes of cerebrovascular ischemic events in patients 
with GCA. Involvement of intracranial/intradural arteries in patients with GCA is a rare 
event and appears to represent a subset of GCA with a fatal course that fails to respond to 
corticosteroids. 
During GCA, strokes occur mostly in the vertebrobasilar territory (as opposed to 
atheromatosis-related CVA). 
Given the frequency of strokes in elderly people, we must discuss the part concerning 
arteritis, steroids side effect and that of atheromatosis. A CVA can occur before the 
treatment begins but also at the beginning of treatment (median of 10 days) (Jouquan et al. 
1984). The thrombosis-producing role of steroids in the genesis of these CVA has been 
reported in several retrospective series. The establishment of a steroid treatment could 
paradoxically favour the onset of cerebral infarcts in patients with intracerebral arteritis and 
does not prevent often fatal precocious ischemic relapses (Salvarani et al. 2009). This 
ischemic risk could be decreased by the association of aspirin at a low dosage (3 % against 
13 %, p= 0.02) with steroids (Nesher et al. 2004; Lee et al. 2006; Robert et al.2006). But in the 
study of Berger et al. (2009) severe ischemic events occurred with high prevalence despite 
established platelet inhibition. Neither platelet count nor size was strongly associated with 
the risk of severe ischemic events (Berger et al. 2009). 
When evaluating patients with dementia, it is common to check for easily reversible 
problems. Both clinicians and researchers should give more attention to looking for GCA as 
a routine part of the standard dementia workup. Mental status changes may be a prominent 
manifestation of GCA and precede and/or overshadow more classic signs and symptoms. 
Depression, agitation, confusion, and focal intellectual impairment have all been described 
(Alisky 2008). 
For example, Morris and Lockie reported in 2005 a 76-year-old man with acute right-sided 
periocular pain and diminished vision. He had a sedimentation rate of 73 mm/hr, 
cilioretinal artery occlusion and “florid” GCA seen on temporal artery biopsy. He was quite 
impaired cognitively, but prednisolone 50 mg per day produced rapid normalisation of his 
mental status, and at that point, his family commented that he had actually had dementia 
for at least a few years. Further investigation revealed that three years before, he had 
suffered a right-sided middle cerebral artery stroke that had been accompanied by scalp 
tenderness and right-sided headache. A diagnosis of GCA had been considered at that time 
but was not pursued because sedimentation rate was only 4 mm/hr.  
Peripheral neurological manifestations can be a mode of revelation of GCA but are 
considered as rare (Reich et al. 1990, Büschges et al. 1984). However, in the series where 
neurological involvement was systemically looked for, the frequency of peripheral 
neuropathies was estimated up to 14 %. In the majority of these cases, it is a sensory-motor 
polyneuropathy which is usually moderate and chronic, a mononeuritis or multineuritis. 
Radicular involvement, which essentially affects the cervical region, is much rarer. Isolated 
plexus brachial syndromes in the scope of multineuritis remain exceptional: no cases in the 
series of 260 GCA by Becourt-Verlomme et al. (2001); one case in 209 proven GCA in the 
series by Blaise et al. (2005). A review of the literature found around twenty observations of 
GCA with histological proof, complicated by a plexus brachial syndrome or low cervical 
radiculopathies on which we wish to focus (Blaise et al. 2005; Soubrier et al. 2002). The 
involvement is often inaugural and quite constantly involves root C5. There is a male 
predominance (54 %) of this complication as opposed to the female predilection for 
www.intechopen.com
 “Extra-Cranial” Manifestations of Giant Cell Arteritis 
 
303 
temporal arteritis. The unilateral or bilateral involvement with no predominant side occurs 
usually at the peak of GCA signs. It sometimes precedes the cephalic signs of GCA by a few 
weeks. Despite the frequent severity of the motor deficit, recuperation is the rule. The 
usually sudden character of the involvement suggests an ischemic mechanism and the 
cervical radiculopathies can be due to a florid giant cell arteritis of the lower radicular 
arteries. Whether ischemic or inflammatory, however, the mechanism of C5–C6 plexopathy 
is pure speculation. 
9. Ophtalmological manifestations 
The incidence of ophthalmological manifestations varies according to studies between 14 % 
and 70 % of cases. In 1998, Hayreh et al. (1998) reported a series of 85 patients suffering from 
GCA for whom opthalmological involvement was listed: amaurosis fugax 30.5%, loss of visual 
acuity 97.6%, diplopia 5.9% and ocular pain 8.2%. Therefore, GCA must be suspected in the 
case of a sudden loss of visual acuity, whether transitory or not, in a patient over 50. This loss 
of visual acuity might be linked to an acute anterior ischemic optical neuropathy 81.2% 
according to Hayreh et al. (1998) or, more rarely, central retinal artery occlusion 14.1%, isolated 
cilioretinal artery occlusion 14.1% and posterior ischemic optic neuropathy in 7%. 
The risk of bilateral ocular involvement is major in the case of GCA. It still occurs in around 
1 case in 4, even though it is avoidable in most of these cases. In the series by Maalouly et al. 
(2010), the average time lapse for a bilateralisation of ocular involvement was 17 days (0 to 
210 days). This was a bilateral ischemic optical neuropathy: anterior 21 times and posterior 
twice, a bilateral retinal central artery occlusion 3 times, an ischemic optical neuropathy 
associated with transitory monocular blindness in the last case. No studied clinical or 
biological parameters were associated with bilateral ocular involvement risks. Ocular 
involvement was inaugural in 5 patients (no general signs). Bilateralisation occurred before 
any steroid treatment 15 times (56 %), 7 times (26 %) at least 5 days after a high dosage 
steroid treatment and 6 times in a longer-term steroid treatment at variable doses. 
Steroids have resulted in a large reduction of the incidence of its ophthalmological 
complications, whose frequency however remains high for two main reasons: delay in 
diagnosis and the existence of ophthalmological complications inaugural of the disease. 
Thus, physicians must be aware of ophthalmological complications of GCA as the severity 
of the disease can be improved by an earlier diagnosis and treatment. 
Berger et al. (2009) have reported a series of 85 GCA patients (78 histologically proven) and 
investigated how platelet count and size and platelet inhibition with aspirin relate to 
ischemic complications. Jaw claudication, amaurosis fugax, blurred vision, ischemic stroke 
and permanent visual loss were classified as “ischemic events”; ischemic stroke and 
permanent visual loss were sub-grouped as “severe ischemic events”. Of the 85 patients, 62 
(73%) presented with ischemic events, 29/85 patients (34%) with severe ischemic events. At 
the time of diagnosis 22/85 patients (26%) were treated with ASA.  In multivariate analysis, 
neither platelet count nor size or aspirin treatment were significantly associated with 
ischemic or severe ischemic events. 
10. Genital involvement 
Genital lesions are exceptional. They can affect the ovaries, the uterus and the tubes. They 
are often discovered by chance, as female patients do not present painful pelvic symptoms. 
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Thus, in a review of the literature, Ducroix et al. (1990) report 11 cases of isolated ovarian 
lesions or associated with a uterine or tube lesion. Clinical signs of rhizomelic 
pseudopolyarthritis were present in four female patients and headaches in two female 
patients. The differential diagnosis of ovarian lesions of GCA is classically periarteritis 
nodosa and Wegener’s disease. These two diseases can have a gynaecological tropism but 
the histological aspect is different.  
11. Musculoskeletal symptoms 
Rhizomelic pseudopolyarthritis is the most frequent rheumatic manifestation of GCA. The 
frequency of rhizomelic pseudopolyarthritis in the course of certified GCA is on average 40 
% (Masson 2010). Conversely, the sub-group of rhizomelic pseudopolyarthritis which does 
not have, at the time of diagnosis, signs suggesting the coexistence of a GCA would only 
appear to have a low risk of developing a GCA later: out of a series of 400 cases of 
rhizomelic pseudopolyarthritis, only four patients (1 %) developed secondarily a clinical 
GCA (Spiera 1990).  
Another work on 230 patients with rhizomelic pseudopolyarthritis with no clinical signs of 
GCA showed that these biopsies of temporal arteries carried out on a sample of 68 
randomly-selected patients were only positive in three cases (4.4 % of the patients) 
(Mykelust et al. 2003). This frequency of 4 % confirms that most rhizomelic 
pseudopolyarthritis with no clinical signs of GCA are actually « pure » rhizomelic 
pseudopolyarthritis. The other rheumatoid manifestations are less frequent. They may be 
polyarthritis, oligoarthritis or monoarthritis affecting the large joints, and specifically the 
knees. The interest of the study by Belcourt-Verlomme et al. (2010)  is above all to highlight 
the existence of monoarthritis or oligoarthritis affecting the large joints preceding GCA (nine 
observations with arthritis affecting large joints,260 with positive temporal artery biopsy in 
seven patients , with a time lapse of up to 24 months and reacting well to non-steroid anti-
inflammatory treatments. Chronic seronegative polyarthritis with a symptomatology 
comparable to rhumatoid arthritis was also described.   In the study of Navaez et al. (2001), 
the records of 163 cases of rhizomelic pseudopolyarthritis or GCA diagnosed over a 15 year 
period in one area of Spain were reviewed for the presence and type of musculo-skeletal 
manifestations. Of 163 patients, 90 had isolated rhizomelic pseudopolyarthritis and 73 had 
GCA. Eighteen of the 90 patients (20%) with isolated rhizomelic pseudopolyarthritis 
developed distal peripheral arthritis either at diagnosis or during the course of the disease. 
When it occurred, synovitis was asymmetrical, transient, and not destructive. Other distal 
manifestations observed in these patients were carpal tunnel syndrome and distal extremity 
swelling with pitting oedema. In all cases these manifestations occurred in conjunction with 
active rhizomelic pseudopolyarthritis. As expected, rhizomelic pseudopolyarthritis was the 
most frequent musculoskeletal manifestation in patient with GCA, occurring in 56% of 
cases. On the contrary, only 11% of patients with GCA developed peripheral arthritis. An 
important finding was that peripheral arthritis in these patients appears to be linked only 
temporally to the presence of simultaneous rhizomelic pseudopolyarthritis and it is not 
observed in its absence. The spectrum of distal musculoskeletal manifestations of rhizomelic 
pseudopolyarthritis in this study is similar to that reported in other populations. By 
contrast, distal musculoskeletal symptoms are uncommon in GCA.  
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When the joint fluid was analyzed, it was not specific. The analyses published in the 
literature show that it is a moderately inflammatory liquid, with less than 3 000 elements, 
and no specificity. 
12. Conclusion 
Giant cell arteritis (GCA) is a primary large-vessel vasculitis predominantly seen in the 
elderly that preferentially involves the external carotid artery and its branches. However, 
inflammation of the aorta and its branches, pericarditis, myocarditis, respiratory 
manifestations, neurologic symptoms including, but not limited to, stroke and blindness, as 
well as musculoskeletal manifestations occur in a subset of patient at diagnosis or during 
the course of the disease. 
Unfortunately, its uncommon findings are frequently overlooked and too often GCA is 
considered a disease of the temporal arteries only. Awareness of the basic anatomy and 
pathophysiology of this disease will enable clinicians to recognize many more obscure 
presentations and provide treatment to prevent serious sequelae. 
Extracranial involvement has probably been underestimated and its incidence may be more 
frequent than suspected. Systematic evaluation of patients with imaging techniques such 
positron emission tomography (PET) may reveal that the clinical impact of extracranial 
involvement by GCA may be more relevant than previously thought. In the setting of GCA 
an early diagnosis is mandatory in order to perform a treatment capable of avoiding the 
chronic and acute complications associated with an elevated mortality.  
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